Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis

ACS Medicinal Chemistry Letters

Volumn 4, Issue 12, 2013, Pages 1238-1243

  Harris, Philip A ^a   Bandyopadhyay, Deepak ^a   Berger, Scott B ^a   Campobasso, Nino ^a   Capriotti, Carol A ^a   Cox, Julie A ^a   Dare, Lauren ^a   Finger, Joshua N ^a   Hoffman, Sandra J ^a   Kahler, Kirsten M ^a   Lehr, Ruth ^a   Lich, John D ^a   Nagilla, Rakesh ^a   Nolte, Robert T ^a   Ouellette, Michael T ^a   Pao, Christina S ^a   Schaeffer, Michelle C ^a   Smallwood, Angela ^a   Sun, Helen H ^a   Swift, Barbara A ^a   Totoritis, Rachel D ^a   Ward, Paris ^a   Marquis, Robert W ^a   Bertin, John ^a   Gough, Peter J ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

necroptosis; RIP1; type II kinase inhibitors

Indexed keywords

1 AMINOISOQUINOLINE; FURO[2,3 D]PYRIMIDINE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PYRROLO[2,3 B]PYRIDINE DERIVATIVE; RECEPTOR INTERACTING PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HYPOTHERMIA; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 84890534620     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400382p     Document Type: Article

References (23)

1. Iyer, S. S.; Pulskens, W. P.; Sadler, J. J.; Butter, L. M.; Teske, G. J.; Ulland, T. K.; Eisenbarth, S. C.; Florquin, S.; Flavell, R. A.; Leemans, J. C.; Sutterwala, F. S. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 20388-20393
2. Bianchi, M. E. DAMPs, PAMPs and alarmins: All we need to know about danger J. Leukocyte Biol. 2007, 81, 1-5
3. Galluzzi, L.; Kroemer, G. Necroptosis turns TNF lethal Immunity 2011, 35, 849-851
4. Degterev, A.; Huang, Z.; Boyce, M.; Li, Y.; Jagtap, P.; Mizushima, N.; Cuny, G. D.; Mitchison, T. J.; Moskowitz, M. A.; Yuan, J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat. Chem. Biol. 2005, 1, 112-119
5. Degterev, A.; Hitomi, J.; Germscheid, M.; Ch'en, I. L.; Korkina, O.; Teng, X.; Abbott, D.; Cuny, G. D.; Yuan, C.; Wagner, G.; Hedrick, S. M.; Gerber, S. A.; Lugovskoy, A.; Yuan, J. Identification of RIP1 kinase as a specific cellular target of necrostatins Nat. Chem. Biol. 2008, 4, 313-321
6. Xu, X.; Chua, K. W.; Chua, C. C.; Liu, C. F.; Hamdy, R. C.; Chua, B. H. Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury Brain Res. 2010, 1355, 189-194
7. Rosenbaum, D. M.; Degterev, A.; David, J.; Rosenbaum, P. S.; Roth, S.; Grotta, J. C.; Cuny, G. D.; Yuan, J.; Savitz, S. I. Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model J. Neurosci. Res. 2010, 88, 1569-1576
8. Linkermann, A.; Bräsen, J. H.; Himmerkus, N.; Liu, S.; Huber, T. B.; Kunzendorf, U.; Krautwald, S. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury Kidney Int. 2012, 81, 751-761
9. Smith, C. C.; Davidson, S. M.; Lim, S. Y.; Simpkin, J. C.; Hothersall, J. S.; Yellon, D. M. Necrostatin: A potentially novel cardioprotective agent? Cardiovasc. Drugs Ther. 2007, 21, 227-233
10. Trichonas, G.; Murakami, Y.; Thanos, A.; Morizane, Y.; Kayama, M.; Debouck, C. M.; Hisatomi, T.; Miller, J. W.; Vavvas, D. G. Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 21695-21700
11. Günther, C.; Martini, E.; Wittkopf, N.; Amann, K.; Weigmann, B.; Neumann, H.; Waldner, M. J.; Hedrick, S. M.; Tenzer, S.; Neurath, M. F.; Becker, C. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis Nature 2011, 477, 335-339
12. Welz, P. S.; Wullaert, A.; Vlantis, K.; Kondylis, V.; Fernández-Majada, V.; Ermolaeva, M.; Kirsch, P.; Sterner-Kock, A.; van Loo, G.; Pasparakis, M. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation Nature 2011, 477, 330-334
13. Bonnet, M. C.; Preukschat, D.; Welz, P. S.; van Loo, G.; Ermolaeva, M. A.; Bloch, W.; Haase, I.; Pasparakis, M. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation Immunity 2011, 35, 572-582
14. Lukens, J. R.; Vogel, P.; Johnson, G. R.; Kelliher, M. A.; Iwakura, Y.; Lamkanfi, M.; Kanneganti, T. D. RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3 Nature 2013, 498, 224-227
15. Xie, T.; Peng, W.; Liu, Y.; Yan, C.; Maki, J.; Degterev, A.; Yuan, J.; Shi, Y. Structural basis of RIP1 inhibition by necrostatins Structure 2013, 21, 493-499
16. Kufareva, I.; Abagyan, R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states J. Med. Chem. 2008, 51, 7921-7932
17. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364
18. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051
19. Washio, Y. Preparation of Aryl Substituted Isoquinoline Derivatives As Inhibitors of VEGFR2, TIE-2, and EphB4. PCT Int. Appl. WO2005049576, 2005.
20. Patnaik, S.; Stevens, K. L.; Gerding, R.; Deanda, F.; Shotwell, J. B.; Tang, J.; Hamajima, T.; Nakamura, H.; Leesnitzer, M. A.; Hassell, A. M.; Shewchuck, L. M.; Kumar, R.; Lei, H.; Chamberlain, S. D. Discovery of 3,5-disubstituted-1 H -pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase Bioorg. Med. Chem. Lett. 2009, 19, 3136-3140
21. Miyazaki, Y.; Tang, J.; Maeda, Y.; Nakano, M.; Wang, L.; Nolte, R. T.; Sato, H.; Sugai, M.; Okamoto, Y.; Truesdale, A. T.; Hassler, D. F.; Nartey, E. N.; Patrick, D. R.; Ho, M. L.; Ozawa, K. Orally active 4-amino-5-diarylurea- furo[2,3- d ]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2 Bioorg. Med. Chem. Lett. 2007, 17, 1773-1778
22. Reaction Biology Corp. http://www.reactionbiology.com.
23. Duprez, L.; Takahashi, N.; Van Hauwermeiren, F.; Vandendriessche, B.; Goossens, V.; Vanden Berghe, T.; Declercq, W.; Libert, C.; Cauwels, A.; Vandenabeele, P. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome Immunity 2011, 35, 908-918